De-risking bio-therapeutics for possible drug interactions using cryopreserved human hepatocytes

Current Drug Metabolism

Volumn 13, Issue 7, 2012, Pages 923-929

  Dallas, Shannon ^a   Sensenhauser, Carlo ^a   Batheja, Ameesha ^a   Singer, Monica ^a   Markowska, Maria ^a   Zakszewski, Cindy ^a   Mamidi, Rao N V S ^a   McMillian, Michael ^a   Han, Chao ^b   Zhou, Honghui ^b   Silva, Jose ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Bio therapeutics; Cryopreserved human hepatocytes; Cytokines; Drug interactions; Interleukin 6; Liver; Tumor necrosis factor

Indexed keywords

AMFEBUTAMONE; AROMATIC HYDROCARBON RECEPTOR; BIOLOGICAL PRODUCT; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOKINE; CYTOKINE ANTIBODY; DEXTROMETHORPHAN; INTERLEUKIN 2; INTERLEUKIN 6; MEPHENYTOIN; MESSENGER RNA; PARACETAMOL; PHENACETIN; PHENOBARBITAL; PREGNANE X RECEPTOR; RETINOID X RECEPTOR ALPHA; RIFAMPICIN; TESTOSTERONE; TOLBUTAMIDE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BIOLOGICAL THERAPY; CONTROLLED STUDY; CRYOPRESERVATION; CYTOKINE PRODUCTION; CYTOTOXICITY; DISEASE ACTIVITY; DRUG METABOLISM; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INFLAMMATORY DISEASE; LIQUID CHROMATOGRAPHY; LIVER CELL; PSORIASIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; RISK REDUCTION;

BIOLOGICAL AGENTS; CHILD, PRESCHOOL; CRYOPRESERVATION; CYTOCHROME P-450 ENZYME SYSTEM; CYTOKINES; DRUG INTERACTIONS; FEMALE; HEPATOCYTES; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84865783988     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012802138589     Document Type: Article

References (24)

1. Huang, S.M.; Zhao, H.; Lee, J.I.; Reynolds, K.; Zhang, L.; Temple, R.; Lesko, L.J. Therapeutic protein-drug interactions and implica-tions for drug development. Clin. Pharmacol. Ther., 2010, 87(4), 497-503.
2. Israel, B.C.; Blouin, R.A.; McIntyre, W.; Shedlofsky, S.I. Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients. Br. J. Clin. Pharmacol., 1993, 36(3), 229-235.
3. Elkahwaji, J.; Robin, M.A.; Berson, A.; Tinel, M.; Letteron, P.; Labbe, G.; Beaune, P.; Elias, D.; Rougier, P.; Escudier, B.; Duvil-lard, P.; Pessayre, D. Decrease in hepatic cytochrome P450 after in-terleukin-2 immunotherapy. Biochem. Pharmacol., 1999, 57(8), 951-954.
4. Gorski, J.C.; Hall, S.D.; Becker, P.; Affrime, M.B.; Culter, D.L.; Haehner-Daniels, B. In vivo effects of interleukin-10 on human cy-tochrome P450 activity. Clin. Pharmacol. Ther., 2000, 67(1), 32-43.
5. Islam, M.; Frye, R.F.; Richards, T.J.; Sbeitan, I.; Donnelly, S.S.; Glue, P.; Agarwala, S.S.; Kirkwood, J.M. Differential effects of IFNα-2b, on the cytochrome P450 enzyme system: a potential ba-sis of IFN toxicity and its modulation by other drugs. Clin. Cancer Res., 2002, 8(8), 2480-2487.
6. Chu, V.; Einolf, H.J.; Evers, R.; Kumar, G.; Moore, D.; Ripp, S.; Silva, J.; Sinha, V.; Sinz, M.; Skerjanec, A. In vitro and in vivo in-duction of cytochrome P450: a survey of the current practices and recommendations: a Pharmaceutical Research and Manufacturers of America perspective. Drug Metab. Dispos., 2009, 37(7), 1339-1354.
7. Aitken, A.E. and Morgan, E.T. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA lev-els in human hepatocytes. Drug Metab. Dispos., 2007, 35(9), 1687-1693.
8. Schmitt, C.; Kuhn, B.; Zhang X., Kivitz, A.J.; Grange, S. Diseasedrug-drug interaction involving tocilizumab and simvastatin in pa-tients with rheumatoid arthritis. Clin. Pharmacol. Ther., 2011, 89(5), 735-740.
9. Dickmann, L.J.; Patel, S.K.; Rock, D.A.; Wienkers, L.C.; Slatter, J.G. Effects of interleukin-6 and an anti-IL-6 (IL-6) monoclonal an-tibody on drug metabolizing enzymes in human hepatocyte culture. Drug Metab. Dispos., 2011, 39(8), 1415-1422.
10. Yang, J.; Hao, C.; Yang, D.; Shi, D.; Song, X.; Luan, X.; Hu, G.; Yan, B. Pregnane X receptor is required for interleukin-6-mediated down-regulation of cytochrome P450 3A4 in human hepatocytes. Tox. Lett., 2010, 197(3), 219-226.
11. Roymans, D.; Annaert, P.; Van Houdt, J.; Weygers, A.; Noukens, J.; Sensenhauser, C.; Silva, J; Van Looveren, C; Hendrickx, J.; Mannens, G.; Meuldermans, W. Expression and induction potential of cytochromes P450 in human cryopreserved hepatocytes. Drug. Metab. Dispos., 2005, 33(7), 1004-1016.
12. Guidance for Industry: Drug Interaction Studies\Study Design, Data Analysis, and Implications for Dosing and Labeling (DRAFT GUIDANCE 2006). http://www.fda.gov/downloads/Drugs/Guida-nceComplianceRegulatoryInformation/ Guidances/ucm072101.pdf Accessed June 19, 2011.
13. Pascussi, J.M.; Gerbal-Chaloin, S.; Pichard-Garcia, L.; Daujat, M.; Fabre, J.M.; Maurel, P.; Vilarem, M.J. Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem. Bio-phys. Res. Commun., 2000, 274(3), 707-713.
14. Greenbaum, D.; Colangelo, C.; Williams, K.; Gerstein, M. Com-paring protein abundance and mRNA expression levels on a ge-nomic scale. Genome Biol., 2003, 4(9), 117.
15. Sunman, J.A.; Hawke, R.L.; LeCluyse, E.L.; Kashuba, A.D. Kupffer cell-mediated IL-2 suppression of CYP3A activity in hu-man hepatocytes. Drug Metab. Dispos., 2004, 32(3), 359-363.
16. Strehlau, J.; Pape, L.; Offner, G.; Nashan, B.; Ehrich, J.H.H. Inter-leukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. Lancet, 2000, 356(9238), 1327-1328.
17. Tacke, F.; Luedde, T.; Trautwein, C. Inflammatory pathways in liver homeostasis and liver injury. Clinic. Rev. Allerg. Immunol., 2009, 36(1), 4-12.
18. rd edition; Ortiz de Montellano, Ed., Kluwer Academic/Plenum Publishers: New York, 2005, pp377-530.
19. Nyagode, B.A.; Lee, C.M.; Morgan, E.T. Modulation of hepatic cytochrome P450s by Citrobacter rodentium infection in interleu-kin-6 and interferon-gamma-null mice. J. Pharmacol. Exp. Ther., 2010, 335(2), 480-488.
20. Wang, H.; Moser, M.; Schiltenwolf, M.; Buchner, M. Circulating cytokines levels compared to pain in patients with fibromyalgia-a prospective longitudinal study over 6 months. J. Rheumatol., 2008, 35(7), 1366-1370.
21. Baumgart, D.C.; Lowder, J.N.; Targan, S.R.; Sandborn, W.J.; Frankel, M.B. Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease. Am. J. Gastroenterol., 2009, 104(4), 868-876.
22. Foster, W.; Carruthers, D.; Lip, G.Y.; Blann, A.D. Inflammatory cytokines, endothelial markers and adhesion molecules in rheuma-toid arthritis: effect of intensive anti-inflammatory treatment. J. Thromb. Thrombolysis, 2010, 29(4), 437-442.
23. Reddy, M.; Torres, G.; McCormick, T.; Marano, C.; Cooper, K.; Yeilding, N.; Wang, Y.; Pendley, C.; Prabhakar, U.; Wong, J.; Davis, C.; Xu, S.; Brodmerkel, C. Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parame-ters. J. Dermatol., 2010, 37(5), 413-425.
24. Hofmann, M.A.; Kiecker, F.; Kuchler, I.; Kors, C.; Trefzer, U. Serum TNF-α, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFNα-2b treatment of patients with melanoma. J. Cancer Res. Clin. Oncol., 2011, 137(3), 455-462.